<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.46793.024</object-id><label>Table 1.</label><caption><title>Possible chemotherapeutic combinations for G4-stabilising ligands with clinically relevant pharmacological drugs</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Oncogene/tumour suppressor</th><th>Combinatorial/single agent</th><th>Available drug treatments</th><th>Cancer association <break/>summary</th><th>Reference</th></tr></thead><tbody><tr><td>BRCA1/2</td><td>Tumour suppressor</td><td>Single agent</td><td>Olaparib CX-5461</td><td>Deficient in ovarian,breast and colorectal cancer.</td><td><xref ref-type="bibr" rid="bib72">Lee et al., 2014</xref>; <break/><xref ref-type="bibr" rid="bib130">Xu et al., 2017</xref>;&#160;<xref ref-type="bibr" rid="bib83">McLuckie et al., 2013</xref>; <xref ref-type="bibr" rid="bib137">Zimmer et al., 2016</xref></td></tr><tr><td>CCDC6</td><td>Tumour suppressor</td><td>Single agent</td><td>Olaparib</td><td>Inactivated in thyroid and lung cancers. CCDC6-deficient tumours are cisplatin-resistant but olaparib sensitive.</td><td><xref ref-type="bibr" rid="bib97">Puxeddu et al., 2005</xref>; <xref ref-type="bibr" rid="bib86">Morra et al., 2015</xref></td></tr><tr><td>CDK12</td><td>Oncogene</td><td>Combinatorial</td><td>Dinaclib (SCH77965)</td><td>High-grade serous ovariancancer, often exhibits gain-of-function CDK12.</td><td><xref ref-type="bibr" rid="bib96">Parry et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Bajrami et al., 2014</xref></td></tr><tr><td>KEAP1</td><td>Oncogene/Tumour suppressor</td><td>Combinatorial/single agent</td><td>CDDO-Me CPUY192018</td><td>KEAP1 inactivated in multiple cancers including thoracic and endometrial; also hasoncogenic role, CDDO-Me used forleukaemia and sold tumours.</td><td><xref ref-type="bibr" rid="bib104">Sanchez-Vega et al., 2018</xref>;&#160;<xref ref-type="bibr" rid="bib1">Abed et al., 2015</xref>;&#160;<xref ref-type="bibr" rid="bib77">Lu et al., 2016</xref>;&#160;<xref ref-type="bibr" rid="bib122">Wang et al., 2014</xref></td></tr><tr><td>PSMC2</td><td>Oncogene</td><td>Combinatorial</td><td>Proteosome inhibitors: Bortezomib CEP187710 Carfizomib</td><td>Ubiquitin is emerging aschemotherapeutic target, and general proteasome inhibitors clinically are used against multiple myeloma.</td><td><xref ref-type="bibr" rid="bib25">Chen et al., 2011a</xref>; <xref ref-type="bibr" rid="bib81">Mattern et al., 2012</xref>;&#160;<xref ref-type="bibr" rid="bib40">Edelmann et al., 2011</xref></td></tr><tr><td>SMAD4</td><td>Tumour suppressor</td><td>Single agent</td><td>GSKi: NCT01632306 NCT01214603 NCT01287520</td><td>Inactivated in 50% of pancreatic adenocarcinomas. Negativelyregulated by GSK, GSKis in clinical trials for metastatic pancreatic cancer and acute leukaemia.</td><td><xref ref-type="bibr" rid="bib106">Schutte et al., 1996</xref>;&#160;<xref ref-type="bibr" rid="bib52">Hahn et al., 1996</xref>; <xref ref-type="bibr" rid="bib36">Demagny and De Robertis, 2016</xref>; <xref ref-type="bibr" rid="bib82">McCubrey et al., 2014</xref></td></tr><tr><td>SRSF10</td><td>Oncogene</td><td>Combinatorial</td><td>E7107 1C8</td><td>Over-expressed in colon cancer. 1C8 inhibits SRSF10 and impairs HIV replication. FUS interactingprotein. E7107 is a splicinginhibitor preventing spliceosome assembly.</td><td><xref ref-type="bibr" rid="bib136">Zhou et al., 2014</xref>;&#160;<xref ref-type="bibr" rid="bib111">Shkreta et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">Cheung et al., 2016</xref>;&#160;<xref ref-type="bibr" rid="bib67">Kotake et al., 2007</xref></td></tr><tr><td>UBA3</td><td>Oncogene</td><td>Combinatorial</td><td>MLN4924</td><td>Upregulated in AML and multiple solid cancers. MLN4924 is in Phase Iclinical trials.</td><td><xref ref-type="bibr" rid="bib113">Soucy et al., 2009</xref></td></tr><tr><td>USP1</td><td>Oncogene/Tumour suppressor</td><td>Combinatorial/single agent</td><td>Pimozide</td><td>Over-expressed inmelanoma, gastric, cervical and NSCLC; under-expressed in leukaemia and lymphoma. Pimozide is a potent USP1-targeting drug.</td><td><xref ref-type="bibr" rid="bib46">Garc&#237;a-Santisteban et al., 2013</xref>; <break/><xref ref-type="bibr" rid="bib26">Chen et al., 2011b</xref></td></tr><tr><td>WEE1</td><td>Oncogene/Tumour suppressor</td><td>Combinatorial/single agent</td><td>AZDMK1775</td><td>Over-expressed in several cancers, some NSCLC are deficient.</td><td><xref ref-type="bibr" rid="bib80">Matheson et al., 2016</xref>;&#160;<xref ref-type="bibr" rid="bib100">Richer et al., 2017</xref>;&#160;<xref ref-type="bibr" rid="bib5">Backert et al., 1999</xref>; <xref ref-type="bibr" rid="bib134">Yoshida et al., 2004</xref></td></tr><tr><td>WHSC1</td><td>Oncogene</td><td>Combinatorial</td><td>DA3003-1 PF-03882845 Chaetocin TC-LPA5-4 ABT-199</td><td>Over-expressed in prostate cancer, multiple myeloma and mantle cell lymphoma. five potent candidate inhibitors.</td><td><xref ref-type="bibr" rid="bib29">Coussens et al., 2017</xref>; <xref ref-type="bibr" rid="bib9">Bennett et al., 2017</xref></td></tr></tbody></table></table-wrap>